Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squa... (rsity in the United States. The universi...)

Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay

Date:10/2/2008

rsity in the United States. The university's emphasis on both learning and research-and on how each complements the other-revolutionized U.S. higher education. Today, Johns Hopkins has ventured from its home in Baltimore to countries throughout the world-China, Italy and Singapore, among many others. It remains a world leader in teaching, patient care and discovery.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNAs. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The first microRNA diagnostic test applying Rosetta Genomics' technology has been approved for clinical use by the State of New York, and the company expects it will be launched by licensed clinical laboratories in the United States in 2008.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease, Rosetta's ability to successfully develop a test differentiating Squamous NSCLC from other NSCLC and the expected timing of commercial launch of tests using Rosetta's microRNA technology, constitute forward-looking s
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
2. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
3. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
4. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
5. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
6. Queens University Chooses Xceeds Ziplex(R) System for Translational Research
7. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
8. The University of Nottingham in the British Midlands Announces Breakthrough in Parkinsons Disease Research
9. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
10. First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan
11. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society

Post Your Comments:

Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squa...(rsity in the United States. The universi...),Health